parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.07 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocyte progenitor cells; strongest in pituicytes/fscs	0.75
chemistry Open Targets	reachable by antibody: liatermin	0.45
trials ClinicalTrials.gov	10 Parkinson's trials, 0 stopped	1.00
literature PubMed	4 Parkinson's papers of 294	0.79
pathways Reactome	4 pathways; mostly growth signalling	0.60

No case: the score is under the bar. Receipt 3995

receipt 4003: GFRA1 in dopamine neurons, braak

power: full sample +0.05 (p 0.854, n 18), 95% CI -0.43 to +0.50. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.08 (p 0.761, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.25 (p 0.315, n 18). could be the mix.
skeptic: leave-one-out range -0.05 to +0.18, sign flips 6; without severely affected donors +0.05 (p 0.854, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for GFRA1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 4002: GFRA1 in oligodendrocytes, braak

power: full sample -0.02 (p 0.949, n 18), 95% CI -0.48 to +0.45. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.05 (p 0.834, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.14 (p 0.567, n 18). could be the mix.
skeptic: leave-one-out range -0.08 to +0.13, sign flips 5; without severely affected donors -0.02 (p 0.949, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for GFRA1 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts